Reneuron Stem Cell Retinitis Pigmentosa

From our ctx human neural stem cell line.

Reneuron stem cell retinitis pigmentosa.

Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying. Reneuron upbeat on retinitis pigmentosa therapy development. We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development. Thu 10 september 2020 16 00 a a a.

Rp is a group of hereditary. Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the.

Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us. 2a clinical trial of its hrpc cell therapy candidate in retinitis pigmentosa. Rene a global leader in the development of cell based therapeutics is pleased to announce positive long term data from the ongoing phase 1 2a clinical trial of its hrpc stem cell therapy candidate in retinitis pigmentosa rp and plans to expand the ongoing study. Our exosomes are derived from our ctx human neural stem cell line.